NCT02849301

Brief Summary

Preterm birth (PTB), defined as birth between 20 and 36 6/7 weeks, is responsible for the majority of the neonatal morbidity and mortality in the United States, and 35% of all U.S. healthcare spending on infants. Globally, about 28% of the 4 million annual neonatal deaths are directly attributable to PTB. Preterm labor (PTL) is the final pathway for about 50% of all PTB. Tocolytic agents are drugs that can slow or stop labor contractions in the attempt to delay births preceded by PTL. Primary tocolysis is defined as tocolysis given on initial presentation of women with PTL. In most of these women, PTL stops, but as their risk of PTB remains high, some have advocated use of maintenance tocolysis, i.e. tocolysis after arrested PTL. So far, no maintenance tocolytic agent has been shown to be beneficial in preventing PTB. The aim of this study is to evaluate the efficacy of maintenance tocolysis with Arabin pessary compared to standard care in singleton gestations with arrested PTL and with short transvaginal ultrasound (TVU) cervical length (CL) \<25mm

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2016

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

July 27, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 29, 2016

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

November 19, 2018

Status Verified

November 1, 2018

Enrollment Period

1.4 years

First QC Date

July 27, 2016

Last Update Submit

November 15, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Spontaneous preterm birth (SPTB)

    Less than 34 weeks gestation

Secondary Outcomes (9)

  • Spontaneous preterm birth (SPTB)

    Less than 37,35,32,28 and 24 weeks gestation

  • Gestational age at delivery

    Delivery (at birth)

  • Latency

    Delivery (at birth)

  • Birth weight

    Delivery (at birth)

  • Admission to neonatal intensive care unit

    Delivery (at birth)

  • +4 more secondary outcomes

Study Arms (2)

Cervical pessary

EXPERIMENTAL

Arabin cervical pessary

Device: Arabin cervical pessary

Standard care

NO INTERVENTION

No treatment

Interventions

Cervical pessary

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • ages
  • Singleton pregnancy
  • (0) - 34(6) weeks of gestation
  • Arrested preterm labor after primary tocolysis
  • Transvaginal ultrasound cervical length less than 25mm at admission
  • Agreement to regular follow-up and provision of written informed consent

You may not qualify if:

  • pessary and no cerclage in situ
  • vaginal bleeding
  • placeta previa/accreta
  • multiple gestations
  • \<24(0) or \>24(6) weeks of gestation
  • Cervical dilatation greater than 3 cm
  • Chorioamnionitis
  • Major fetal abnormalities
  • Abruptio placentae
  • PPROM
  • Polyhydramnios or oligohydramnios
  • IUGR/FGR with or without Doppler abnormalities
  • Preeclampsia or pregnancy-related hypertension

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Naples Federico II

Naples, 80100, Italy

Location

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

July 27, 2016

First Posted

July 29, 2016

Study Start

July 1, 2016

Primary Completion

December 1, 2017

Study Completion

March 1, 2018

Last Updated

November 19, 2018

Record last verified: 2018-11

Locations